Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics in Switzerland and the United States. The company uses its proprietary, genome-wide and CRISPR-enabled SNIPRx platform to discover and develop cancer therapies that treat cancers due to mechanisms of genomic instability, including DNA damage repair. It also develops camonsertib (RP-3500), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase that is in Phase 1/2 clinical trial for the treatment of solid tumors; and lunresertib (RP-6306), a selective and potent oral small molecule inhibitor of Protein Kinase Membrane-associated tyrosine-and threonine-specific cdc-2 inhibitory kinase that is in Phase 1/2 clinical trial. In addition, the company is developing RP-1664, an oral PLK4 inhibitor in Phase 1 clinical trial to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, an inhibitor of adenosinetriphosphatase activity on the helicase domain of DNA polymerase theta that is in Phase 1 clinical trial. The company has strategic collaborations with Hoffmann-La Roche Inc., F. HoffmannLa Roche Ltd, Debiopharm International S.A., Bristol-Myers Squibb Company, Ono Pharmaceutical Company Ltd., and New York University. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montreal, Canada. Show more

Location: 7171 Frederick-Banting, Building 2, Montreal, QC, H4S 1Z9, Canada | Website: https://www.reparerx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

67.34M

52 Wk Range

$0.89 - $4.29

Previous Close

$1.57

Open

$1.55

Volume

3,277,248

Day Range

$1.37 - $1.55

Enterprise Value

-63.24M

Cash

124.2M

Avg Qtr Burn

-29.38M

Insider Ownership

1.25%

Institutional Own.

69.46%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 3

Initiation

Phase 2

Data readout

Phase 1/2

Update

RP-1664 Details
Cancer, Neuroblastoma

Phase 1/2

Initiation

RP-1664 Details
Cancer, Solid tumor/s

Phase 1

Data readout

RP-3467 +/- olaparib Details
Solid tumor/s, Cancer

Phase 1

Data readout

Failed

Discontinued

Failed

Discontinued